August 2012 | OncologyLive

Rash Signals Better Outcome for Erlotinib Therapy in NSCLC

September 05, 2012

Cutaneous rash is a common adverse event among patients with non-small cell lung cancer who receive erlotinib and may indicate that the patient will experience a significantly greater survival benefit.

Drug Shortage Dilemma: Trying New Tactics in a Tough Arena

August 29, 2012

Fresh strategies for grappling with the chronic, and at times critical, shortages of cancer drugs that have frustrated the oncology community for the past decade are likely to help alleviate supply problems.

Cabozantinib Shows Promise as Potent RET Inhibitor in MTC

August 22, 2012

The ability of cabozantinib to inhibit the RET pathway contributed to the pivotal clinical trial findings demonstrating that the novel oral agent significantly improved PFS in patients with advanced MTC.